Using a new form of Tacrolimus after liver transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of Envarsus, an extended-release formulation of Tacrolimus, in patients who have undergone liver transplantation. The goal is to determine if this new formulation can reduce side effects commonly associated with Tacrolimus, such as kidney dysfunction and neurotoxicity, while maintaining effective immunosuppression. Participants will be monitored for clinical outcomes, including liver function and hospitalization rates, to assess the overall impact of this medication compared to standard Tacrolimus. The study aims to improve post-transplant care and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Adult individuals transplanted at the University of Alberta

Exclusion Criteria:

* Individuals with congenital long QT syndrome
* Patients with elevated bilirubin \> 100 umol/L post-LT (at day 3)
* Patients with chronic kidney disease (eGFR \< 45 ml per minute per 1.73 m2)
* Patients with acute kidney injury requiring discontinuation of calcineurin inhibitors.
* Patients who have hepatocellular carcinoma, require a re-transplant, or receive multi-visceral transplant

Where it's running

• Univerity of Alberta
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Study coordinator: Rahima A Bhanji, MD
• Email: rbhanji@ualberta.ca
• Phone: 780-492-2235

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Health Ahead: Comparing AI vs. Humans for Preventive Health Screening

  This study tests AI-assisted screening interpretation against human-only reads to see if automated screening can match or improve current practice for adults, especially in underserved areas.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07669168

• How environment and biology together predict health, aging, and death

  Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07646782

• 100-Year Human Aging and Longevity Tracking Program

  This project will follow adults over their lifetimes to see if repeated health tests can predict lifespan, causes of death, serious disease, and loss of function.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07563777

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Pre-screening to identify adults who may be eligible for future metabolic and mental health opportunities.

  This prescreening will see if adults with metabolic conditions or mental health disorders qualify for upcoming clinical opportunities by collecting health history, basic tests, and a doctor interview.

  Recruiting Clindove Research LLC · Brooklyn, New York · NCT07106879

• Survey to determine eligibility for cardiovascular and obesity clinical trials

  This study is trying to see if people with heart issues or obesity can join new clinical trials by having them fill out a survey and undergo some health checks.

  Recruiting Brooklyn Clinical Research · Brooklyn, New York · NCT06412536

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.